Literature DB >> 218763

Computed tomography of supratentorial astrocytoma.

J T Tans, I E de Jongh.   

Abstract

In a group of 40 astrocytomas the C.T. appearance was correlated with the grade of malignancy. On the plain scan the majority presented an irregular, nonhomogeneous low density lesion, better demarcatable in high than in low grade astrocytomas. Contrast enhancement was seen in 28 of the 32 high grade astrocytomas, 50% of the annular, 25% of the nodular and 25% of the mixed type. Six of the 8 low grade astrocytomas showed no contrast enhancement and 1 showed an annular type lesion. A relationship was found between the degree of contrast enhancement and the vascularity. Mass effect was observed in all but 1 patient, but more pronounced in high grade astrocytomas. At the first interpretation 98% were recognized as a lesion, 93% as a tumor and 68% as an astrocytoma. One false negative and no false postive C.T.scans were obtained. In review, high and low grade malignancies were correctly differentiated in 90%. As a screening method, the combination of EEG and echo equalled C.T.; in establishing a definite diagnosis angiography was inferior to C.T. Solely on the basis of the C.T. appearance, astrocytomas can hardly be differentiated from the other malignant brain tumors, but the grade of malignancy can be predicted reliably.

Entities:  

Mesh:

Year:  1978        PMID: 218763     DOI: 10.1016/s0303-8467(78)80037-7

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  2 in total

1.  Early MRI findings in high grade glioma.

Authors:  H J Landy; T T Lee; P Potter; L Feun; A Markoe
Journal:  J Neurooncol       Date:  2000-03       Impact factor: 4.130

2.  Gliomatosis cerebri: clinical characteristics, management, and outcomes.

Authors:  Selby Chen; Shota Tanaka; Caterina Giannini; Jonathan Morris; Elizabeth S Yan; Jan Buckner; Daniel H Lachance; Ian F Parney
Journal:  J Neurooncol       Date:  2013-01-23       Impact factor: 4.130

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.